- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:29 | Biodesix Surges On Strong Preliminary Q4 And FY2025 Revenue Results | 3 | RTTNews | ||
| BIODESIX Aktie jetzt für 0€ handeln | |||||
| 13:24 | Biodesix skyrockets 43%, expects FY revenue to beat guidance | 3 | Seeking Alpha | ||
| 12:30 | Biodesix reports 41% revenue growth in Q4, exceeds 2025 guidance | 2 | Investing.com | ||
| 12:06 | Biodesix, Inc.: Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited) | 74 | GlobeNewswire (Europe) | Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjusted EBITDA positivity in Q4 2025.... ► Artikel lesen | |
| 03.12.25 | Biodesix, Inc.: Biodesix to Present New Data at Two Major Upcoming Scientific Meetings | 2 | GlobeNewswire (USA) | ||
| 04.11.25 | Biodesix: Canaccord bestätigt Kaufempfehlung nach starken Q3-Zahlen | 2 | Investing.com Deutsch | ||
| 04.11.25 | Biodesix stock maintains Buy rating at Canaccord after strong Q3 results | 1 | Investing.com | ||
| 04.11.25 | Biodesix raises 2025 revenue guidance to $84M-$86M as primary care expansion accelerates | 4 | Seeking Alpha | ||
| 03.11.25 | Biodesix GAAP EPS of -$1.16 beats by $0.35, revenue of $21.8M beats by $0.82M | 1 | Seeking Alpha | ||
| 03.11.25 | Biodesix, Inc.: Biodesix Announces Third Quarter 2025 Results and Highlights | 115 | GlobeNewswire (Europe) | Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024; Q3 2025 gross profit margin of 81%, a 400-basis point improvement from Q3 2024; Raised FY2025 Total Revenue Guidance to $84-86 million... ► Artikel lesen | |
| 03.11.25 | BIODESIX INC - 10-Q, Quarterly Report | - | SEC Filings | ||
| 03.11.25 | BIODESIX INC - 8-K, Current Report | - | SEC Filings | ||
| 31.10.25 | What's Next: Biodesix's Earnings Preview | 2 | Benzinga.com | ||
| 30.10.25 | Biodesix, Inc.: Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 22.10.25 | Biodesix stock rises after expanded Bio-Rad partnership | 1 | Investing.com | ||
| 22.10.25 | Biodesix to validate ESR1 mutation test for advanced breast cancer | 1 | Investing.com | ||
| 22.10.25 | Biodesix validiert ESR1-Mutationstest für fortgeschrittenen Brustkrebs | 1 | Investing.com Deutsch | ||
| 22.10.25 | Biodesix, Inc.: Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital PCR High Complexity Assays | 304 | GlobeNewswire (Europe) | LOUISVILLE, Colo., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NYSE: BDSX), a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which... ► Artikel lesen | |
| 15.10.25 | Biodesix, Inc.: Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 06.10.25 | Biodesix, Inc.: Biodesix Unveils October Lung Health Events in Colorado with the Association of Pulmonary Advanced Practice Providers (APAPP), American Lung Association in Colorado, and GO2 for Lung Cancer Centers of Excellence Summit | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BEAM THERAPEUTICS | 33,690 | +22,29 % | Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition | Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints U.S. Biologics Licensing Application (BLA)... ► Artikel lesen | |
| QIAGEN | 40,930 | -0,73 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,040 | -13,41 % | Summit Therapeutics Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 4,830 | +3,65 % | RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| DAY ONE BIOPHARMACEUTICALS | 11,330 | +26,73 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 18,080 | -2,27 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| CG ONCOLOGY | 53,73 | -0,87 % | CG Oncology Inc.: CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial... ► Artikel lesen | |
| BIONTECH | 87,55 | +1,92 % | BioNTech-Aktie: Ein guter Kauf für 2026? | Seit Anfang Dezember 2025 tritt die BioNTech-Aktie bei Kursen um die 96 US$ auf der Stelle. Auch zum Jahresstart zeigt sie wenig Bewegung. Sehen Anleger hier keine guten Investmentchancen für 2026?... ► Artikel lesen | |
| ALUMIS | 21,090 | +7,82 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,35 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 26,780 | -5,10 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,935 | -0,08 % | ADMA Biologics reports FY 2025 revenue in line with estimate, provides 2026-2029 outlook | ||
| EVOTEC | 6,464 | +2,83 % | Evotec Aktie: Das große Comeback im Jahr 2026? | Nächster Anlauf der Evotec Aktie auf große charttechnische Kaufsignale - bisher misslangen diese Ausbruchsversuche. Nachdem die Biotech-Aktie in den letzten Tagen zunächst an der Unterstützung bei 5... ► Artikel lesen | |
| ABIVAX | 102,80 | +4,05 % | Abivax: NBC-Volltreffer explodiert erneut - wird die Übernahme jetzt besiegelt? | Der US-Pharmakonzern Eli Lilly prüft eine der größten Übernahmen im europäischen Biotechnologiesektor: Rund 15 Milliarden Euro könnte demnach der Kauf der französischen Biotech-Gesellschaft Abivax kosten.... ► Artikel lesen | |
| LEXEO THERAPEUTICS | 8,120 | -22,96 % | Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy | LX2020 generally well tolerated across ten participants with no clinically significant complement activation LX2020 transduction, transcription, and increased protein expression observed across participants... ► Artikel lesen |
BIODESIX INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +47,99 % bei einem Aktienkurs von 8,080 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIODESIX INC finden Sie auf Wallstreet Online.